please find enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech reported a sharp fall in profitability despite modest revenue growth. Standalone revenue from operations rose to ₹1,301.66 lakhs in Q2 FY26 (up ~8% YoY from ₹1,203.51 lakhs), while H1 revenue grew ~15% to ₹2,543.52 lakhs. However, standalone Q2 net profit plunged to ₹86.92 lakhs (down ~84% from ₹531.27 lakhs) and H1 net profit fell ~59% to ₹224.24 lakhs, largely because other income collapsed to ₹13.39 lakhs from ₹463.10 lakhs last year. Employee costs and finance charges remained heavy, squeezing margins sharply. The company allotted 22.07 lakh equity shares via warrant conversion on a preferential basis during the quarter. The auditor (P. Murali & Co.) issued an unmodified review report on both standalone and consolidated results.
Mixed picture for shareholders — top line is growing but bottom line has collapsed YoY on fading one-time other income and elevated costs, which may weigh on the stock. The negative operating cash flow of ₹966 lakhs (standalone H1) shows core operations are not yet self-funding, although the ₹1,666 lakh equity infusion from warrant conversion has strengthened the balance sheet (total equity up to ₹9,709 lakhs). Watch for sustained margin recovery in coming quarters.